ANTIFLU

Innovative anti-influenza drugs excluding viral escape

 Coordinatore MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. 

 Organization address address: Hofgartenstrasse 8
city: MUENCHEN
postcode: 80539

contact info
Titolo: Ms.
Nome: Birgit
Cognome: Gieding
Email: send email
Telefono: +49 30 28460 125
Fax: +49 30 28460 242

 Nazionalità Coordinatore Germany [DE]
 Totale costo 7˙821˙684 €
 EC contributo 5˙999˙998 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-INFLUENZA-2010
 Funding Scheme CP-FP
 Anno di inizio 2011
 Periodo (anno-mese-giorno) 2011-06-01   -   2016-05-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.

 Organization address address: Hofgartenstrasse 8
city: MUENCHEN
postcode: 80539

contact info
Titolo: Ms.
Nome: Birgit
Cognome: Gieding
Email: send email
Telefono: +49 30 28460 125
Fax: +49 30 28460 242

DE (MUENCHEN) coordinator 1˙459˙128.00
2    LEAD DISCOVERY CENTER GMBH

 Organization address address: OTTO HAHN STRASSE 15
city: DORTMUND
postcode: 44227

contact info
Titolo: Dr.
Nome: Michael
Cognome: Hamacher
Email: send email
Telefono: +49 231 9742 7012
Fax: +49 231 9742 7039

DE (DORTMUND) participant 1˙099˙860.00
3    VICHEM CHEMIE KUTATO KFT

 Organization address address: HERMANN OTTO UTCA 15
city: BUDAPEST
postcode: 1022

contact info
Titolo: Prof.
Nome: György
Cognome: Kéri
Email: send email
Telefono: +36 1 4872080
Fax: +36 1 7999990

HU (BUDAPEST) participant 596˙500.00
4    AARHUS UNIVERSITET

 Organization address address: Nordre Ringgade 1
city: AARHUS C
postcode: 8000

contact info
Titolo: Ms.
Nome: Karin
Cognome: Sutherland
Email: send email
Telefono: +45 89 42 55 48

DK (AARHUS C) participant 536˙576.00
5    ARTTIC

 Organization address address: Rue du Dessous des Berges 58A
city: PARIS
postcode: 75013

contact info
Titolo: Mr.
Nome: Bruno
Cognome: Cucinelli
Email: send email
Telefono: +33 1 53 94 54 61
Fax: +33 1 53 94 54 70

FR (PARIS) participant 420˙000.00
6    IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE

 Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
city: LONDON
postcode: SW7 2AZ

contact info
Titolo: Ms.
Nome: Tatjana
Cognome: Palalic
Email: send email
Telefono: +44 207 594 3866
Fax: +44 207 594 3868

UK (LONDON) participant 403˙778.00
7    FORSCHUNGSVERBUND BERLIN E.V.

 Organization address address: Rudower Chaussee 17
city: BERLIN
postcode: 12489

contact info
Titolo: Dr.
Nome: Anne
Cognome: Höner
Email: send email
Telefono: +49 30 94793286
Fax: +49 30 94793109

DE (BERLIN) participant 400˙000.00
8    MEDITOX S.R.O

 Organization address address: POD ZAMKEM 279
city: KONAROVICE
postcode: 28125

contact info
Titolo: Mr.
Nome: Jan
Cognome: Zabsky
Email: send email
Telefono: +420 313 129 374
Fax: +420 313 129 366

CZ (KONAROVICE) participant 333˙556.00
9    RiboTask ApS

 Organization address address: UNSBJERGVEJ 2 A
city: Odense SO
postcode: DK-5220

contact info
Titolo: Dr.
Nome: Jesper
Cognome: Wengel
Email: send email
Telefono: +45 2084 6872
Fax: +45 6315 0023

DK (Odense SO) participant 300˙000.00
10    THE HEBREW UNIVERSITY OF JERUSALEM.

 Organization address address: GIVAT RAM CAMPUS
city: JERUSALEM
postcode: 91904

contact info
Titolo: Ms.
Nome: Hani
Cognome: Ben-Yehuda
Email: send email
Telefono: +972 2 6586676
Fax: +972 2 6513205

IL (JERUSALEM) participant 250˙560.00
11    INSTITUT PASTEUR

 Organization address address: RUE DU DOCTEUR ROUX 25-28
city: PARIS CEDEX 15
postcode: 75724

contact info
Titolo: Dr.
Nome: Nadia
Cognome: Khelef
Email: send email
Telefono: +33 1 4061 3378
Fax: +33 1 4061 3940

FR (PARIS CEDEX 15) participant 200˙040.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

will    infections    pandemic    strains    antiflu    against    treatment    virus    influenza    innovative    anti    clinical    host    potent    factors    drugs    human    trials    viral    molecules    seasonal   

 Obiettivo del progetto (Objective)

'ANTIFLU is to develop innovative drugs against influenza virus infections based on a novel concept that precludes the development of viral resistance and ensures efficacy against upcoming pandemic influenza strains. Viral replication is known to depend on multiple host factors. Whilst traditional anti-influenza treatments usually target viral factors, ANTIFLU will aim at drugs interfering with host-response pathways. The concept of drugs targeting human factors, established in treatment of other diseases, has yet not been sufficiently explored for treatment of viral infections, although it bears compelling advantages over conventional antiviral therapies: (i) the avoidance of viral escape mutants and (ii) the broad coverage against unprecedented viral variants. ANTIFLU aims to fully exploit this potent approach to fill critical gaps in our current treatment and prevention options against seasonal and pandemic influenza virus infections. By building upon an existing panel of potent human targets and firm knowledge derived from FP6 project RIGHT, an interdisciplinary consortium will pursue the identification and validation of small molecule ligands and inhibitory RNA molecules effective against influenza infection. Promising modulators will form the basis to generate lead molecules that will be further refined to yield clinically applicable therapeutics. Initial preclinical studies will aim at providing proof of concept in animal models, safety and toxicology profiles. They will allow initiating complete clinical trials immediately after the phase of FP7 support, thanks to the commitment already taken by investors from the private sector. The consortium includes several SMEs, internationally renowned research groups and clinical institutions with extensive experience in anti-influenza treatment and clinical trials. An already agreed common exploitation model will provide a smooth route to market and optimal use of the project results.'

Introduzione (Teaser)

Seasonal influenza infections and the threat of pandemic viral strains scream for innovative measures. The European ANTIFLU study proposes to target the host instead of the virus itself.

Altri progetti dello stesso programma (FP7-HEALTH)

REPAIR-HD (2013)

"Human pluripotent stem cell differentiation, safety and preparation for therapeutic transplantation in Huntington’s disease"

Read More  

NABATIVI (2009)

"Novel Approaches to Bacterial Target Identification, Validation and Inhibition"

Read More  

METFIZZ (2013)

Metformin for treatment of polycystic ovary syndrome in children

Read More